Stock: fury shares.
Fury shares (300049): leading liver disease. This company has a liver disease whole industry chain medical service platform, the main diagnostic products for the Fibroscan series of liver fibrosis diagnostic instrument, is the world's first non-invasive liver fibrosis detection equipment; hold 13.01% of the equity of France Median, which is a high-end tumor imaging software provider; 17 years of medical equipment revenue of 494 million, accounting for 58.09%.
The company's main business is drug production and sales, diagnostic equipment development and sales, and O2O heavy vertical chronic liver disease management medical service business.
Furui features:
The company is a pharmaceutical manufacturing and medical service provider focusing on the field of liver disease, and its main business is divided into three main areas: pharmaceutical manufacturing and sales of Compound Tetramethylene Soft Liver Tablets as the leading product; the world's exclusive and innovative quantitative detection of liver stiffness and steatosis "Fibroscan"? series of medical devices; is building a vertically integrated chronic liver on-line prolapse disease management platform, providing related medical services, and agent sales of related drugs.